|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yutong H, Xiaoli X, Shumei L, Shan S, Di L
and Baoen S: Increased neutrophil-lymphocyte ratio is a poor
prognostic factor in patients with esophageal cancer in a high
incidence area in China. Arch Med Res. 46:557–563. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Toh Y, Oki E, Ohgaki K, Sakamoto Y, Ito S,
Egashira A, Saeki H, Kakeji Y, Morita M, Sakaguchi Y, et al:
Alcohol drinking, cigarette smoking, and the development of
squamous cell carcinoma of the esophagus: Molecular mechanisms of
carcinogenesis. Int J Clin Oncol. 15:135–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moon DH, Jeon JH, Yang HC, Kim YI, Lee JY,
Kim MS, Lee JM and Lee GK: Intramural metastasis as a risk factor
for recurrence in esophageal squamous cell carcinoma. Ann Thorac
Surg. 106:249–256. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu H, Chen S, Yu J, Li Y, Zhang XY, Yang
L, Zhang H, Hou Q, Jiang M, Brunicardi FC, et al: Single-cell
transcriptome analyses reveal molecular signals to intrinsic and
acquired paclitaxel resistance in esophageal squamous cancer cells.
Cancer Lett. 420:156–167. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oksenych V and Coin F: The long unwinding
road: XPB and XPD helicases in damaged DNA opening. Cell Cycle.
9:90–96. 2010. View Article : Google Scholar
|
|
7
|
Lerner LK, Moreno NC, Rocha CRR, Munford
V, Santos V, Soltys DT, Garcia CCM, Sarasin A and Menck CFM:
XPD/ERCC2 mutations interfere in cellular responses to oxida-tive
stress. Mutagenesis. 34:341–354. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Minina VI, Bakanova ML, Soboleva OA,
Ryzhkova AV, Titov RA, Savchenko YA, Sinitsky MY, Voronina EN,
Titov VA and Glushkov AN: Polymorphisms in DNA repair genes in lung
cancer patients living in a coal-mining region. Eur J Cancer Prev.
28:522–528. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nigam K, Yadav SK, Samadi FM, Bhatt ML,
Gupta S and Sanyal S: Risk modulation of oral pre cancer and cancer
with polymorphisms in XPD and XPG genes in North Indian population.
Asian Pac J Cancer Prev. 20:2397–2403. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xiao Z, Wang Y and Ding H: XPD suppresses
cell proliferation and migration via miR-29a-3p-Mdm2/PDGF-B axis in
HCC. Cell Biosci. 9:62019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ding H, Xu JJ, Huang Y, Du FT and Zhang
JX: XPD could suppress growth of HepG2.2.15 and down-regulate the
expression of hepatitis B virus x protein through P53 pathway.
Biochem Biophys Res Commun. 419:761–767. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang DH, Jian J, Li S, Zhang Y and Liu
LZ: TPX2 silencing exerts anti-tumor effects on hepatocellular
carcinoma by regulating the PI3K/AKT signaling pathway. Int J Mol
Med. 44:2113–2122. 2019.PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
14
|
Wang L, Zhang Z, Yu X, Li Q, Wang Q, Chang
A, Huang X, Han X, Song Y, Hu J, et al: SOX9/miR-203a axis drives
PI3K/AKT signaling to promote esophageal cancer progression. Cancer
Lett. 468:14–26. 2020. View Article : Google Scholar
|
|
15
|
Zheng TL, Li DP, He ZF and Zhao S: MiR-145
sensitizes esophageal squamous cell carcinoma to cisplatin through
directly inhibiting PI3K/AKT signaling pathway. Cancer Cell Int.
19:2502019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou J, Zheng S, Liu T, Liu Q, Chen Y, Tan
D, Ma R and Lu X: MCP2 activates NF-κB signaling pathway promoting
the migration and invasion of ESCC cells. Cell Biol Int.
42:365–372. 2018. View Article : Google Scholar
|
|
17
|
Lu Z, Lu C, Li C, Jiao Y, Li Y and Zhang
G: Dracorhodin perchlorate induces apoptosis and G2/M cell cycle
arrest in human esophageal squamous cell carcinoma through
inhibition of the JAK2/STAT3 and AKT/FOXO3a pathways. Mol Med Rep.
20:2091–2100. 2019.PubMed/NCBI
|
|
18
|
Wang WW, Zhao ZH, Wang L, Li P, Chen KS,
Zhang JY, Li WC, Jiang GZ and Li XN: MicroRNA-134 prevents the
progression of esophageal squamous cell carcinoma via the
PLXNA1-mediated MAPK signalling pathway. EBioMedicine. 46:66–78.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
20
|
Wiedmann MW and Mössner J: New and
emerging combination therapies for esophageal cancer. Cancer Manag
Res. 5:133–146. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ohashi S, Miyamoto S, Kikuchi O, Goto T,
Amanuma Y and Muto M: Recent advances from basic and clinical
studies of esophageal squamous cell carcinoma. Gastroenterology.
149:1700–1715. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hong H, Jie H, Liyu R, Zerui C, Borong S
and Hongwei L: Prognostic significance of middle paraesophageal
lymph node metastasis in resectable esophageal squamous cell
carcinoma: A STROBE-compliant retrospective study. Medicine
(Baltimore). 98:e175312019. View Article : Google Scholar
|
|
23
|
Zhao Y, Han L, Zhang W, Shan L, Wang Y,
Song P, Peng C and Zhao X: Preoperative chemotherapy compared to
postoperative adjuvant chemotherapy for squamous cell carcinoma of
the thoracic oesophagus with the detection of circulation tumour
cells randomized controlled trial. Int J Surg. 73:1–8. 2020.
View Article : Google Scholar
|
|
24
|
Zhang Z, Xu L, Di X, Zhang C, Ge X and Sun
X: A retrospective study of postoperative radiotherapy for locally
advanced esophageal squamous cell carcinoma. Ann Palliat Med.
8:708–716. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guan Q, Chen Z, Chen Q and Zhi X: XRCC1
and XPD polymorphisms and their relation to the clinical course in
hepa-tocarcinoma patients. Oncol Lett. 14:2783–2788. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoon HH, Catalano PJ, Murphy KM, Skaar TC,
Philips S, Powell M, Montgomery EA, Hafez MJ, Offer SM, Liu G, et
al: Genetic variation in DNA-repair pathways and response to
radio-chemotherapy in esophageal adenocarcinoma: A retrospective
cohort study of the eastern cooperative oncology group. BMC Cancer.
11:1762011. View Article : Google Scholar
|
|
27
|
Engin AB, Karahalil B, Engin A and
Karakaya AE: DNA repair enzyme polymorphisms and oxidative stress
in a Turkish population with gastric carcinoma. Mol Biol Rep.
38:5379–5386. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang MY, Wang JY, Huang ML, Chang HJ and
Lin SR: Polymorphisms in XPD and ERCC1 associated with colorectal
cancer outcome. Int J Mol Sci. 14:4121–4134. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zheng JF, Li LL, Lu J, Yan K, Guo WH and
Zhang JX: XPD functions as a tumor suppressor and dysregulates
autophagy in cultures HepG2 cells. Med Sci Monit. 21:1562–1568.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Javadinia SA, Shahidsales S, Fanipakdel A,
Mostafapour A, Joudi-Mashhad M, Ferns GA and Avan A: The esophageal
cancer and the PI3K/AKT/mTOR signaling regulatory microRNAs: A
novel marker for prognosis, and a possible target for
immuno-therapy. Curr Pharm Des. 24:4646–4651. 2018. View Article : Google Scholar
|
|
31
|
Han B, Jiang P, Li Z, Yu Y, Huang T, Ye X
and Li X: Coptisine-induced apoptosis in human colon cancer cells
(HCT-116) is mediated by PI3K/Akt and mitochondrial-associated
apoptotic pathway. Phytomedicine. 48:152–160. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang Y, Zhang J, Hou L, Wang G, Liu H,
Zhang R, Chen X and Zhu J: LncRNA AK023391 promotes tumorigenesis
and invasion of gastric cancer through activation of the PI3K/Akt
signaling pathway. J Exp Clin Cancer Res. 36:1942017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Parveen A, Akash MS, Rehman K and Kyunn
WW: Dual role of p21 in the progression of cancer and its
treatment. Crit Rev Eukaryot Gene Expr. 26:49–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang D, Qi J, Liu R, Dai B, Ma W, Zhan Y
and Zhang Y: c-Myc plays a key role in TADs-induced apoptosis and
cell cycle arrest in human hepatocellular carcinoma cells. Am J
Cancer Res. 5:1076–1088. 2015.PubMed/NCBI
|
|
35
|
Cheng G, Zhang L, Lv W, Dong C, Wang Y and
Zhang J: Overexpression of cyclin D1 in meningioma is associated
with malignancy grade and causes abnormalities in apoptosis,
invasion and cell cycle progression. Med Oncol. 32:4392015.
View Article : Google Scholar
|
|
36
|
Alam M, Kashyap T, Pramanik KK, Singh AK,
Nagini S and Mishra R: The elevated activation of NFκB and AP-1 is
correlated with differential regulation of Bcl-2 and associated
with oral squamous cell carcinoma progression and resistance. Clin
Oral Investig. 21:2721–2731. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Su F, Geng J, Li X, Qiao C, Luo L, Feng J,
Dong X and Lv M: SP1 promotes tumor angiogenesis and invasion by
activating VEGF expression in an acquired trastuzumab-resistant
ovarian cancer model. Oncol Rep. 38:2677–2684. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao G, Zhang H, Huang Z, Lv L and Yan F:
Cortactin and Exo70 mediated invasion of hepatoma carcinoma cells
by MMP-9 secretion. Mol Biol Rep. 43:407–414. 2016. View Article : Google Scholar : PubMed/NCBI
|
